Annual Net Income
-$12.85 M
+$29.58 M+69.71%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual net profit is -$12.85 million, with the most recent change of +$29.58 million (+69.71%) on March 1, 2024.
- During the last 3 years, GRCE annual net income has risen by +$6.83 million (+34.68%).
- GRCE annual net income is now -871.65% below its all-time high of -$1.32 million, reached on February 1, 2015.
Performance
GRCE Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$3.43 M
-$815.00 K-31.14%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly net profit is -$3.43 million, with the most recent change of -$815.00 thousand (-31.14%) on September 1, 2024.
- Over the past year, GRCE quarterly net income has dropped by -$1.04 million (-43.54%).
- GRCE quarterly net income is now -120.66% below its all-time high of $16.61 million, reached on March 1, 2020.
Performance
GRCE Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$11.61 M
-$159.00 K-1.39%
September 1, 2024
Summary
- As of February 8, 2025, GRCE TTM net profit is -$11.61 million, with the most recent change of -$159.00 thousand (-1.39%) on September 1, 2024.
- Over the past year, GRCE TTM net income has increased by +$27.17 million (+70.07%).
- GRCE TTM net income is now -549.32% below its all-time high of $2.58 million, reached on December 1, 2020.
Performance
GRCE TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
GRCE Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +69.7% | -43.5% | +70.1% |
| 3 y3 years | +34.7% | +30.4% | +32.3% |
| 5 y5 years | +67.3% | +83.8% | +36.0% |
GRCE Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -30.9% | +69.7% | -43.5% | +88.2% | -18.2% | +72.7% |
| 5 y | 5-year | -30.9% | +69.7% | -120.7% | +88.2% | -549.3% | +79.3% |
| alltime | all time | -871.6% | +69.7% | -120.7% | +88.2% | -549.3% | +79.3% |
Grace Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.43 M(+31.1%) | -$11.61 M(+1.4%) |
| Jun 2024 | - | -$2.62 M(-17.3%) | -$11.45 M(-10.9%) |
| Mar 2024 | -$12.85 M(-69.7%) | -$3.17 M(+32.4%) | -$12.85 M(-66.9%) |
| Dec 2023 | - | -$2.39 M(-26.9%) | -$38.77 M(-3.7%) |
| Sep 2023 | - | -$3.27 M(-18.6%) | -$40.27 M(-3.9%) |
| Jun 2023 | - | -$4.02 M(-86.2%) | -$41.93 M(-1.2%) |
| Mar 2023 | -$42.43 M(+332.1%) | -$29.09 M(+647.9%) | -$42.43 M(+146.0%) |
| Dec 2022 | - | -$3.89 M(-21.1%) | -$17.25 M(+0.6%) |
| Sep 2022 | - | -$4.93 M(+9.0%) | -$17.14 M(+52.7%) |
| Jun 2022 | - | -$4.52 M(+15.9%) | -$11.22 M(+14.3%) |
| Mar 2022 | -$9.82 M(-50.1%) | -$3.90 M(+3.3%) | -$9.82 M(-15.1%) |
| Dec 2021 | - | -$3.78 M(-485.1%) | -$11.56 M(+5.1%) |
| Sep 2021 | - | $981.00 K(-131.5%) | -$11.00 M(-39.3%) |
| Jun 2021 | - | -$3.12 M(-44.8%) | -$18.13 M(-7.9%) |
| Mar 2021 | -$19.68 M(-22.9%) | -$5.65 M(+75.3%) | -$19.68 M(-861.8%) |
| Dec 2020 | - | -$3.22 M(-47.6%) | $2.58 M(-140.9%) |
| Sep 2020 | - | -$6.15 M(+31.7%) | -$6.32 M(-70.4%) |
| Jun 2020 | - | -$4.67 M(-128.1%) | -$21.33 M(-16.4%) |
| Mar 2020 | -$25.51 M(-35.2%) | $16.61 M(-237.1%) | -$25.51 M(-54.4%) |
| Dec 2019 | - | -$12.12 M(-42.7%) | -$55.97 M(+18.5%) |
| Sep 2019 | - | -$21.16 M(+139.2%) | -$47.23 M(+8.2%) |
| Jun 2019 | - | -$8.85 M(-36.1%) | -$43.67 M(+7.9%) |
| Mar 2019 | -$39.37 M(+136.4%) | -$13.85 M(+309.1%) | -$40.46 M(+24.0%) |
| Dec 2018 | - | -$3.38 M(-80.8%) | -$32.64 M(-4.3%) |
| Sep 2018 | - | -$17.59 M(+211.8%) | -$34.09 M(+69.3%) |
| Jun 2018 | - | -$5.64 M(-6.3%) | -$20.13 M(+21.1%) |
| Mar 2018 | -$16.65 M(+97.4%) | -$6.02 M(+24.6%) | -$16.63 M(+56.8%) |
| Dec 2017 | - | -$4.83 M(+33.1%) | -$10.60 M(+40.4%) |
| Sep 2017 | - | -$3.63 M(+70.1%) | -$7.55 M(+32.5%) |
| Jun 2017 | - | -$2.14 M(+19.7%) | -$5.70 M(-22.5%) |
| Mar 2017 | -$8.43 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2016 | - | -$1.78 M(+0.3%) | -$7.35 M(+2.0%) |
| Aug 2016 | - | -$1.78 M(-26.4%) | -$7.21 M(+13.2%) |
| May 2016 | - | -$2.42 M(+76.2%) | -$6.37 M(+34.7%) |
| Feb 2016 | -$4.66 M(+252.4%) | -$1.37 M(-16.2%) | -$4.73 M(-10.0%) |
| Nov 2015 | - | -$1.64 M(+74.9%) | -$5.25 M(+435.5%) |
| Aug 2015 | - | -$936.90 K(+20.6%) | -$980.10 K(-71.7%) |
| May 2015 | - | -$777.10 K(-59.0%) | -$3.46 M(+141.8%) |
| Feb 2015 | -$1.32 M(-87.3%) | -$1.90 M(-172.1%) | -$1.43 M(-0.5%) |
| Nov 2014 | - | $2.63 M(-177.0%) | -$1.44 M(-81.3%) |
| Aug 2014 | - | -$3.41 M(-373.1%) | -$7.70 M(+4.7%) |
| May 2014 | - | $1.25 M(-165.7%) | -$7.36 M(-30.0%) |
| Feb 2014 | -$10.44 M(+55.0%) | -$1.90 M(-47.6%) | -$10.51 M(+1.4%) |
| Nov 2013 | - | -$3.63 M(+18.2%) | -$10.37 M(+24.0%) |
| Aug 2013 | - | -$3.07 M(+61.1%) | -$8.36 M(+18.5%) |
| May 2013 | - | -$1.91 M(+8.3%) | -$7.05 M(+5.7%) |
| Feb 2013 | -$6.73 M(+3.0%) | -$1.76 M(+8.5%) | -$6.68 M(+0.3%) |
| Nov 2012 | - | -$1.62 M(-8.1%) | -$6.66 M(-7.2%) |
| Aug 2012 | - | -$1.76 M(+15.4%) | -$7.17 M(+0.1%) |
| May 2012 | - | -$1.53 M(-12.1%) | -$7.17 M(+7.2%) |
| Feb 2012 | -$6.54 M(+112.6%) | -$1.74 M(-18.6%) | -$6.69 M(+8.0%) |
| Nov 2011 | - | -$2.14 M(+21.4%) | -$6.19 M(+32.9%) |
| Aug 2011 | - | -$1.76 M(+68.1%) | -$4.66 M(+30.7%) |
| May 2011 | - | -$1.05 M(-15.9%) | -$3.56 M(+17.6%) |
| Feb 2011 | -$3.08 M(+103.9%) | -$1.25 M(+105.5%) | -$3.03 M(+38.7%) |
| Nov 2010 | - | -$605.80 K(-9.1%) | -$2.19 M(+11.6%) |
| Aug 2010 | - | -$666.30 K(+29.6%) | -$1.96 M(+13.7%) |
| May 2010 | - | -$514.00 K(+28.5%) | -$1.72 M(+16.0%) |
| Feb 2010 | -$1.51 M | -$400.10 K(+5.9%) | -$1.48 M(+36.9%) |
| Nov 2009 | - | -$377.80 K(-12.1%) | -$1.08 M(+21.1%) |
| Aug 2009 | - | -$429.80 K(+55.2%) | -$895.60 K(+92.3%) |
| May 2009 | - | -$277.00 K(+46.7%) | -$465.80 K(+146.7%) |
| Nov 2008 | - | -$188.80 K | -$188.80 K |
FAQ
- What is Grace Therapeutics annual net profit?
- What is the all time high annual net income for Grace Therapeutics?
- What is Grace Therapeutics annual net income year-on-year change?
- What is Grace Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Grace Therapeutics?
- What is Grace Therapeutics quarterly net income year-on-year change?
- What is Grace Therapeutics TTM net profit?
- What is the all time high TTM net income for Grace Therapeutics?
- What is Grace Therapeutics TTM net income year-on-year change?
What is Grace Therapeutics annual net profit?
The current annual net income of GRCE is -$12.85 M
What is the all time high annual net income for Grace Therapeutics?
Grace Therapeutics all-time high annual net profit is -$1.32 M
What is Grace Therapeutics annual net income year-on-year change?
Over the past year, GRCE annual net profit has changed by +$29.58 M (+69.71%)
What is Grace Therapeutics quarterly net profit?
The current quarterly net income of GRCE is -$3.43 M
What is the all time high quarterly net income for Grace Therapeutics?
Grace Therapeutics all-time high quarterly net profit is $16.61 M
What is Grace Therapeutics quarterly net income year-on-year change?
Over the past year, GRCE quarterly net profit has changed by -$1.04 M (-43.54%)
What is Grace Therapeutics TTM net profit?
The current TTM net income of GRCE is -$11.61 M
What is the all time high TTM net income for Grace Therapeutics?
Grace Therapeutics all-time high TTM net profit is $2.58 M
What is Grace Therapeutics TTM net income year-on-year change?
Over the past year, GRCE TTM net profit has changed by +$27.17 M (+70.07%)